DURHAM, N.C., Feb. 7 /PRNewswire/ -- Serenex, Inc., an integrated oncology-focused drug discovery and development company, announced today that Dr. Richard Kent, chief executive officer, is scheduled to present at the BIO CEO & Investor Conference, taking place February 12th to the 14th, 2007, at the Waldorf-Astoria in New York City.
On February 14 at 3:45 p.m., Dr. Kent will give a corporate presentation in the Conrad Suite. During the presentation Dr. Kent will provide an overview of the company including recent progress, strategy, and ongoing development programs.
A replay of the presentation will be available under the "News" section of the Serenex website (www.serenex.com) approximately 12 hours after the presentation for a period of 90 days.
About Serenex
Serenex is an integrated oncology-focused drug discovery and development company. Serenex's lead program, SNX-1012, a product for chemotherapy and radiation-induced oral mucositis in solid tumor patients, is scheduled to complete phase 2 clinical trials in Q4 2007. Oral mucositis, which represents a large and underserved market, frequently causes clinicians to interrupt therapy which directly leads to decreased rates of efficacy. Additionally, Serenex has a novel pre-clinical small molecule inhibitor of Heat Shock Protein 90 (Hsp90) which is scheduled to begin clinical trials in April 2007. Hsp90 is a central protein responsible for chaperoning a large number of oncogenic proteins (such as Her2 and Raf) that are necessary to support cancer cell survival and growth. Serenex's pipeline is powered by a proprietary high throughput screening platform which enables the company to profile compounds, en masse, against thousands of important therapeutic and toxicity targets. Website: www.serenex.com.
Serenex, Inc.CONTACT: Ian Howes, CFO & Sr. V.P. Corporate Development, Serenex, Inc.,+1-919-281-6001, or ihowes@serenex.com, or Michelle Linn, LinndenCommunications, +1-508-419-1555, or linnmich@comcast.net
Company News On-Call: http://www.prnewswire.com/comp/638776.html /
